Literature DB >> 12695163

Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis.

P A Klimiuk1, S Sierakowski, R Latosiewicz, J P Cylwik, B Cylwik, J Skowronski, J Chwiecko.   

Abstract

OBJECTIVE: To examine the relation between the serum levels of tumour necrosis factor alpha (TNFalpha), soluble tumour necrosis factor receptors (sTNF-R), and the histological pattern of rheumatoid synovitis.
METHODS: An enzyme linked immunosorbent assay (ELISA) was used to measure TNFalpha, p55 sTNF-R, and p75 sTNF-R concentrations in the serum of 43 patients with rheumatoid arthritis (RA) and 34 patients with osteoarthritis (OA).
RESULTS: Upon histological analysis two variants of rheumatoid synovitis emerged. Twenty six RA specimens presented only diffuse infiltrates of mononuclear cells. In the remaining 17 samples the formation of lymphocytic follicles with germinal centre-like structures was found. Serum concentrations of TNFalpha, p55 and p75 sTNF-R were raised in patients with RA compared with the OA control group (p<0.001 for all comparisons). Levels of TNFalpha, p55 and p75 sTNF-R were higher in the serum of patients with RA with follicular synovitis than in patients with diffuse synovitis (p<0.001, p<0.01, and p<0.05, respectively). Serum concentrations of TNFalpha, p55 and p75 sTNF-R correlated with markers of disease activity.
CONCLUSION: Different histological types of rheumatoid synovitis associated with distinct serum levels of TNFalpha and sTNF-R reflect varying clinical activity of the disease and support the concept of RA heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695163      PMCID: PMC1754528          DOI: 10.1136/ard.62.5.472

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.

Authors:  A Kuuliala; R Nissinen; H Kautiainen; H Repo; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2005-06-07       Impact factor: 19.103

Review 2.  Oral Complications of Chronic Graft-Versus-Host Disease.

Authors:  Jane M Fall-Dickson; Steven Z Pavletic; Jacqueline W Mays; Mark M Schubert
Journal:  J Natl Cancer Inst Monogr       Date:  2019-08-01

Review 3.  Cellular and molecular perspectives in rheumatoid arthritis.

Authors:  Douglas J Veale; Carl Orr; Ursula Fearon
Journal:  Semin Immunopathol       Date:  2017-05-15       Impact factor: 9.623

4.  Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.

Authors:  M van Oosterhout; E W N Levarht; J K Sont; T W J Huizinga; R E M Toes; J M van Laar
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

Review 5.  Synovial tissue heterogeneity and peripheral blood biomarkers.

Authors:  Serena Bugatti; Antonio Manzo; Michele Bombardieri; Barbara Vitolo; Frances Humby; Stephen Kelly; Carlomaurizio Montecucco; Costantino Pitzalis
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

6.  Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.

Authors:  Jane M Fall-Dickson; Sandra A Mitchell; Susan Marden; Edward S Ramsay; Jean-Pierre Guadagnini; Tianxia Wu; Lena St John; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-06       Impact factor: 5.742

Review 7.  The role of chemokines in leucocyte-stromal interactions in rheumatoid arthritis.

Authors:  Andrew Filer; Karim Raza; Mike Salmon; Christopher D Buckley
Journal:  Front Biosci       Date:  2008-01-01

8.  Soluble TNF receptors are produced at sites of inflammation and are inversely associated with self-reported symptoms (WOMAC) in knee osteoarthritis.

Authors:  Adriano Prado Simão; Tássio Málber de Oliveira Almeida; Vanessa Amaral Mendonça; Sérgio Antunes Santos; Wellington Fabiano Gomes; Cândido Celso Coimbra; Ana Cristina Rodrigues Lacerda
Journal:  Rheumatol Int       Date:  2014-04-20       Impact factor: 2.631

9.  Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis.

Authors:  H Schotte; B Schlüter; S Drynda; P Willeke; N Tidow; G Assmann; W Domschke; J Kekow; M Gaubitz
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

10.  Assessment of synovitis to predict bone erosions in rheumatoid arthritis.

Authors:  Serena Bugatti; Antonio Manzo; Roberto Caporali; Carlomaurizio Montecucco
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-08       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.